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Objectives. This study was designed to examine whether the
myocardium can be maintained in a protected state by extending
the delayed phase of cardioprotection with chronic, intermittent
adenosine A1 receptor activation.
Background. Several recent studies have explored the temporal
characteristics of the protective effects of ischemic precondition-
ing. Two distinct phases of myocardial protection have been
described: the short-lived immediate phase, or “classic” pre-
conditioning, and the delayed phase, or “second window of
protection” (SWOP). Previous studies have examined the poten-
tial for extending the duration of classic preconditioning by
repeated application of the preconditioning stimulus. Pretreat-
ment with either multiple episodes of ischemia or continuous
infusion of a selective adenosine A1 receptor agonist, 2-chloro-N
6-
cyclopentyladenosine (CCPA), resulted in attenuation of the pro-
tective effects of preconditioning, implying downregulation of the
receptors involved in triggering classic preconditioning.
Methods. Male New Zealand White rabbits were treated with
repeated intravenous boluses of CCPA, 100 mg/kg body weight, or
0.9% saline at 48-h intervals. Forty-eight hours after the fifth dose
(day 10), the animals were anesthetized and subjected to 30 min of
coronary occlusion, followed by 120 min of reperfusion. Infarct
size was determined as a percentage of myocardial risk volume
using tetrazolium staining. To further explore whether the rabbits
had developed tolerance to the effects of adenosine A1 receptor
activation, a subgroup of animals were treated with a further
bolus of CCPA, 100 mg/kg, at the end of the reperfusion period,
and the hemodynamic response was monitored for 10 min before
excision of the heart.
Results. Pretreatment with intermittent doses of CCPA resulted
in a 42% reduction in the infarct to risk ratio compared with
vehicle pretreatment (26.6 6 3.7% vs. 45.9 6 5.5%, p < 0.01).
Furthermore, CCPA treatment at the end of reperfusion resulted
in identical hypotension and bradycardia in both groups.
Conclusions. We conclude that rabbits can be maintained in a
protected state against myocardial infarction by repeated activa-
tion of adenosine A1 receptors, with no evidence of tachyphylaxis
to the infarct-limiting or hemodynamic effects of CCPA. This
finding suggests that adenosine A1 receptor activation may hold
promise as a new approach to long-term cardioprotection.
(J Am Coll Cardiol 1998;31:1142–9)
©1998 by the American College of Cardiology
Ischemic preconditioning (IPC), defined as enhanced myocar-
dial resistance to ischemic necrosis after brief periods of
ischemia and reperfusion (1), has been recognized as the most
powerful experimental means of attaining myocardial protec-
tion. It is now established in most animal species studied that
IPC induces a biphasic pattern of myocardial protection. An
immediate period of cardioprotection, “classic precondition-
ing,” lasts ;60 to 120 min after the preconditioning stimulus
and is then lost (2,3). This is followed, after a delay of 12 to
24 h, by a distinct phase of enhanced tolerance to ischemia
(4–7), which, although not as powerful as the early phase, is
more prolonged and lasts up to 72 h (8–10). This delayed
phase of resistance to ischemia has been termed the “second
window of protection” (SWOP) (11).
The precise cellular mechanisms underlying the protective
effects of preconditioning are not known. There are several
lines of evidence suggesting a role for a number of endogenous
paracrine mediators acting as triggers of both phases of
myocardial protection (12). In particular, endogenous adeno-
sine, released by myocytes and vascular endothelium during
periods of ischemia or acting on adenosine A1 and A3 recep-
tors, has been implicated as a trigger of both phases of
myocardial protection after IPC. Blockade of adenosine recep-
tors during preconditioning has been reported to abolish both
the early (13) and the late (14) cardioprotective effects of IPC.
Furthermore, substitution of the IPC with intravenous admin-
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istration of selective adenosine A1 receptor agonists induces
both early (15,16) and late (14) protection against infarction.
All these data point to a therapeutic potential for adenosine
A1 receptor agonists in ischemic heart disease. However, the
main shortcoming of such therapy is that it would have to be
given as a pretreatment to patients at risk of coronary throm-
bosis. Such pretreatment could be achieved, however, if the
duration of the protection afforded by preconditioning was
extended, thereby maintaining the myocardium in a precondi-
tioned state over a long period. A recent study by Tsuchida et
al. (17) addressed the possibility of maintaining classic precon-
ditioning by using a continuous infusion of 2-chloro-N6-
cyclopentyladenosine (CCPA) in a rabbit model of infarction,
induced by 30 min of regional ischemia followed by 3 h of
reperfusion. Rabbits subjected to a 6-h infusion of CCPA
showed a 59% reduction in infarct size compared with the
saline-treated rabbits. Infarction in a group receiving a 72-h
infusion of CCPA, however, was the same as in the 72-h vehicle
group. Furthermore, the protective effects of a 5-min ischemic
preconditioning stimulus were attenuated after a 72-h infusion
of CCPA. The group that received a 72-h infusion of saline,
however, was preconditioned with 5 min of ischemia. These
investigators concluded that myocytes become desensitized to
the protective effects of CCPA with prolonged exposure, and
that such tachyphylaxis also abolished the beneficial effects of
IPC. In separate experiments, the same group examined the
effect of multiple 5-min episodes of regional ischemia in a
conscious, chronically instrumented rabbit model (18). Ani-
mals subjected to 40 to 65 five-minute coronary occlusions over
a 3- to 4-day period showed a marked attenuation in infarct
size limitation compared with the animals that had been
preconditioned with a single 5-min occlusion.
Although these studies have partially addressed the ques-
tion of prolonging the early phase of myocardial protection, as
yet there are no reports of experiments exploring the possible
extension of SWOP. We performed preliminary studies to
confirm previous observations that delayed cardioprotection is
induced after transient adenosine A1 receptor activation. We
then examined whether this delayed phase of myocardial
protection can be maintained over a long period by long-term
intermittent adenosine A1 receptor activation. In particular,
we wished to establish whether this schedule of long-term
dosing would maintain or increase the degree of myocardial
protection, or whether tachyphylaxis would result from cumu-
lative dosing.
Methods
Male New Zealand White rabbits weighing 2.2 to 3.5 kg
were used in these experiments. All procedures were in
accordance with U.K. Home Office guidelines on the Animals
(Scientific Procedures) Act of 1986, published by Her Majes-
ty’s stationery office. The animals were housed in individual
cages and had free access to food and water throughout the
preparation period.
Single-dose studies. Preliminary studies were performed to
confirm our previous observations that a delayed phase of
myocardial protection is induced after transient adenosine A1
receptor activation (14). CCPA (Research Biochemicals Inc.,
through Semat, St. Albans, United Kingdom) was dissolved in
sterile 0.9% sodium chloride injection (British Pharmacopoeia).
Conscious rabbits were randomized to receive a single bolus of
CCPA (100 mg/kg body weight) or saline vehicle (0.5 ml) by
intravenous injection through a marginal ear vein. Twenty-four
or 48-h later, the animals were subjected to 30 min of regional
myocardial ischemia and 120 min reperfusion in vivo, and the
infarct size was determined as described subsequently (Fig. 1).
Long-term intermittent dosing study. On the basis of these
preliminary studies and previous studies from our laboratory
characterizing the time course of the delayed protection con-
ferred by A1 receptor activation (19), the schedule for inter-
mittent dosing of animals was determined. Conscious rabbits
were treated with repeated intravenous boluses of CCPA
(100 mg/kg) or saline vehicle (0.5 ml) at 48-h intervals. The
treatments were administered on a random basis and the
animals were returned to their cages with no further manipu-
lation between the treatments. Approximately 48 h after the
fifth dose (day 10), the animals were subjected to an infarction
procedure in vivo and the infarct size was measured (Fig. 1).
Infarction procedure. At the end of the pharmacologic
preconditioning protocols, all animals were subjected to an
acute myocardial infarction procedure. Rabbits were premed-
icated with Hypnorm, 0.15 ml/kg intramuscularly (obtained
from Janssen Pharmaceuticals, containing fentanyl citrate [315
mg/ml] and fluanisone [10 mg/ml]) and anesthetized with
pentobarbital sodium, 30 mg/kg intravenously. Thereafter,
Hypnorm, 0.1 ml/kg intramuscularly, and pentobarbital so-
dium, 5 to 10 mg/kg intravenously, were administered as
required to maintain surgical anesthesia. A midline incision
was made in the neck and a tracheostomy was performed. The
animals were intubated and mechanically ventilated with a
positive-pressure respirator and room air supplemented with
oxygen at a rate of 1 Hz (small animal ventilator, Harvard
Apparatus). The right common carotid artery was cannulated
with a rigid polyethylene cannula connected to a pressure
transducer (Lectromed UK Ltd.) for periodic hemodynamic
and arterial blood gas measurements. Tidal volume was ad-
justed as necessary to maintain arterial pH between 7.35 and
Abbreviations and Acronyms
CCPA 5 2-chloro-N6-cyclopentyladenosine
ECG 5 electrocardiogram, electrocardiographic
HR 5 heart rate
I 5 infarct volume
IPC 5 ischemic preconditioning
R 5 risk zone volume
RPP 5 rate–pressure product
SBP 5 systolic blood pressure
SWOP 5 second window of protection
TTC 5 triphenyltetrazolium chloride
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7.50. The core temperature was measured intermittently by a
rectal thermometer and maintained at 38.5 6 0.5°C by a
heating pad. Electrocardiographic (ECG) leads were attached
to limbs to obtain a single-channel ECG, which was used for
continuous monitoring of heart rate, arrhythmias and ST
segment changes. A median sternotomy was performed and
the pericardium was incised to expose the heart. A 3-0 silk
suture (Mersilk type 546, Ethicon) on an atraumatic needle
was passed around a prominent anterolateral branch of the left
coronary artery approximately half way between the left atrial
appendage and the apex. The ends of the suture were threaded
through a polypropylene tube to form a snare. Regional
myocardial ischemia was induced by pulling the snare taut
against the myocardium and clamping it into position. Isch-
emia was confirmed by the presence of regional left ventricular
hypokinesia and epicardial cyanosis associated with ST seg-
ment elevation on the ECG. After 30 min of ischemia, the
snare was released and reperfusion confirmed by conspicuous
reactive hyperemia of the risk zone and return of ST segments
to normal. The myocardium was reperfused for 120 min.
Risk zone and infarct size assessment. At the end of
120 min of reperfusion, the rabbits were anticoagulated with
500 IU of heparin intravenously. The animals were killed with
an overdose of pentobarbital and the heart was excised and
immediately attached to a Langendorff apparatus through the
aortic root and retrogradely perfused with cold saline to
remove blood. The coronary suture was ligated and the aortic
root perfused with 2 to 4 ml of a 5-mg/ml suspension of 1 to
10 mm of zinc cadmium sulfide microspheres (Duke Scientific)
to define the risk zone. Under ultraviolet light the tissue
supplied by the occluded branch was nonfluorescent. The
hearts were then weighed, frozen at 218°C and cut into 2-mm
slices from apex to base perpendicular to the long axis of the
heart. After defrosting, the slices were incubated at 37°C in a
1% solution of triphenyltetrazolium chloride (TTC) in phos-
phate buffer (pH 7.4) for 15 to 20 min and fixed for 24 to 48 h
in 4% vol/vol formalin solution. TTC stains normal myocar-
dium red, whereas infarct-related tissue appears pale or gray.
The slices were traced on acetate sheets, infarcted areas were
outlined and fluorescent and nonfluorescent areas were distin-
guished under ultraviolet light. The areas of infarct-related
tissue (I) and myocardium at risk (R) were determined by
using computerized planimetry (Summa Sketch II, Summa
Graphics), and the corresponding volumes were calculated by
multiplication of each area by slice thickness.
Hemodynamic effects of CCPA. The early hemodynamic
effects of an intravenous bolus of CCPA, 100 mg/kg, in
anesthetized rabbits have been described by us previously (14).
To further explore whether rabbits pretreated with CCPA for
10 days had developed tolerance to the effects of adenosine A1
receptor activation, a subgroup of animals (6 per group) were
treated with a further bolus of CCPA, 100 mg/kg, at the end of
the reperfusion period, and the hemodynamic response was
monitored for 10 min before excision of the heart. This
involved measurement of systolic blood pressure (SBP) and
heart rate (HR) at baseline (at the end of 120 min of
reperfusion) and at 1, 2, 3, 5 and 10 min after the CCPA bolus.
Statistical analysis. The data are presented throughout as
mean values 6 SEM. The significance of differences in mean
values of I, R and I/R between the two treatment groups was
evaluated by the Student unpaired t test. Any differences
between hemodynamic variables at different time points was
assessed by two-way analysis of variance with repeated mea-
sures, followed by the Fisher least significant differences test
used post hoc for individual differences. The null hypothesis
was rejected at p # 0.05.
Results
A total of 54 rabbits were used for these studies. Thirty
were used for the single-dose studies and 24 for the long-term
intermittent dosing study. In the single-dose studies, two rabbit
hearts were excluded owing to intractable ventricular fibrilla-
tion during the infarct protocol (one in 48-h vehicle group and
one in 24-h CCPA group); one was excluded owing to failure
of the TTC stain (24-h CCPA group); and one was excluded
Figure 1. Protocol for pharmacologic precondi-
tioning. A, In single-dose studies, the animals
were treated with a single 100-mg/kg bolus of
CCPA 24 or 48 h before the infarct procedure. B,
In the long-term intermittent dosing study, the
animals were treated at 48-h intervals over a
period of 10 days with repeated boluses of CCPA
and subjected to an infarction procedure on day
10. Arrows represent a single intravenous bolus
of CCPA, 100 mg/kg, or saline vehicle. Isch 5
ischemia.
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owing to absence of a risk zone (48-h CCPA group). In the
long-term intermittent dosing study, four hearts were ex-
cluded: one owing to severe ventricular fibrillation during the
infarction protocol, two owing to embolization at the time of
microsphere infusion for risk zone determination and one
owing to the coronary artery being punctured at the time of
insertion of the suture (all in CCPA group). We therefore
report data on 46 animals that successfully completed the two
studies.
Single-dose studies. Table 1 represents the infarct size and
risk volume data for rabbits pharmacologically preconditioned
with CCPA at 24 and 48 h before the infarct procedure. Figure
2 represents the I/R ratios graphically. CCPA administration
24 h before infarction resulted in a reduction in the I/R ratio
from 41.3 6 4.4% in the vehicle group to 23.0 6 3.9% in the
CCPA group (p , 0.05). The corresponding values for the 48-h
CCPA and vehicle groups were 37.7 6 2.9% and 26.1 6 3.0%,
respectively (p , 0.05). There were no differences in hemody-
namic variables (Table 2), body temperature or arterial pH
(data not shown for brevity) at any time points between the
various groups. These data confirm previous results from our
laboratory indicating that a delayed phase of myocardial
protection is induced 24 and 48 h after transient A1 receptor
activation (19).
Long-term intermittent dosing study. Systemic hemody-
namic changes during ischemia-reperfusion. Table 3 summa-
rizes the changes in HR and rate–pressure product (RPP)
during the infarction protocol in animals pretreated for 10 days
with intermittent (every 48 h) CCPA/vehicle administration.
There were no differences in baseline RPP values between the
two groups. There was a small decline in RPP during the
30 min of ischemia with no recovery during reperfusion. This
was mainly due to a reduction in SBP, as HR remained
relatively unchanged throughout the infarct protocol. The
hemodynamic changes with time, however, were very similar in
the two groups and are therefore unlikely to have contributed
to the differences in infarct size.
Infarct size data. Absolute infarct size and risk zone vol-
umes are presented in Table 4 for saline- and CCPA-
pretreated animals. Figure 3 represents infarct size as a
percentage of area at risk. Intermittent CCPA pretreatment
caused a marked resistance to myocardial infarction compared
with vehicle pretreatment (control), indicating that the delayed
phase of cardioprotection was present at 10 days of repeated
adenosine A1 receptor activation. The I/R ratio in CCPA-
pretreated animals was 26.6 6 3.7% compared with 45.9 6
5.5% in control animals (p , 0.01). Risk zone volume, a major
determinant of infarct size, was similar between the two groups
and averaged at 1.1 to 1.2 cm3. Arterial pH and body temper-
ature were also similar in the two groups at all time points
(data not shown).
Early hemodynamic effects of CCPA after long-term treat-
ment. Figure 4 illustrates the early effects of a 100-mg/kg bolus
of CCPA administered at the end of the reperfusion period in
animals pretreated for 10 days with intermittent CCPA or
vehicle. Baseline variables were similar in both groups (CCPA-
pretreated group: HR 227 6 9 beats/min, SBP 75 6 3 mm Hg;
vehicle-pretreated group: HR 237 6 10 beats/min, SBP 73 6
4 mm Hg). There was a rapid decline in HR and blood
pressure, which was very similar in the two groups. By 10-min
after CCPA administration, there was a 20.0 6 2.4% reduction
in SBP and a 28.3 6 2.8% reduction in HR in the saline-
pretreated group compared with 18.9 6 1.8% and 29.1 6 3.4%,
respectively, in the CCPA-pretreated group (p 5 NS). This
similarity in the hemodynamic response after a bolus of CCPA
in the two groups provides strong evidence that rabbits ex-
posed to 10 days of repeated administration had not developed
tolerance to the effects of the adenosine A1 receptor agonist.
Discussion
These studies provide further evidence of a delayed phase
of myocardial protection induced 24 and 48 h after transient
adenosine A1 receptor activation and support previous results
Table 1. Infarct Size Data for Single-Dose Studies
Group
No. of
Animals
Body
Weight
(kg)
Risk
Volume
(cm3)
Infarct
Volume
(cm3)
Saline
24 h 6 2.63 6 0.22 0.94 6 0.19 0.40 6 0.09
48 h 6 2.39 6 0.08 0.95 6 0.15 0.36 6 0.07
CCPA
24 h 7 2.64 6 0.15 1.07 6 0.08 0.25 6 0.05
48 h 7 2.49 6 0.08 1.06 6 0.08 0.29 6 0.05
Data presented are mean value 6 SEM. CCPA 5 2-chloro-N6-cyclo-
pentyladenosine.
Figure 2. Percent infarction of the risk zone in single-dose studies.
The figure represents the reduction in infarct size 24 or 48 h after a
single intravenous bolus of CCPA, compared with time-matched
vehicle (Veh) treatment. Open circles indicate individual experiments;
solid circles represent the mean value 6 SEM for each group. *p ,
0.05 versus time-matched vehicle-treated group (unpaired Student t
test).
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from our laboratory (19). Furthermore, we have shown for the
first time that this SWOP can be maintained over a 10-day
period by intermittent pharmacologic preconditioning with an
A1 receptor agonist, with no evidence of tachyphylaxis to the
infarct-limiting or hemodynamic effects of CCPA. The resil-
ience against myocardial infarction seen in rabbits precondi-
tioned over the long term with intermittent CCPA was com-
parable to that seen at 24 and 48 h after a single dose of CCPA.
Moreover, after 10 days of pretreatment, the early hemody-
namic response to a bolus of CCPA was no different in animals
that had received either CCPA or saline pretreatment, provid-
ing further evidence that myocytes had not developed toler-
ance to the effects of the A1-selective agonist.
No development of tachyphylaxis. In the present study we
did not measure the hemodynamic effects of CCPA, 100 mg/kg,
in conscious rabbits during the 10-day preconditioning proto-
col, although it is likely that the early hemodynamic response
is less pronounced in conscious animals than in anesthetized
animals. Furthermore, in our previous study describing the
early hemodynamic response to a 100-mg/kg bolus of CCPA in
anesthetized rabbits (14), the bradycardia and hypotension
induced by the A1 receptor agonist had completely resolved by
90 min after administration, implying that the compound is
eliminated within a few hours. It is therefore unlikely that the
marked anti-infarct effects observed after 10 days of pretreat-
ment with intermittent CCPA had resulted from the transient
bradycardia and hypotension induced after the administration
of the agonist. In addition, because the hemodynamic variables
at the start of the infarction procedure were similar between
the two groups, there is no evidence to suggest cumulative
hemodynamic effects of the A1 receptor agonist over the
10-day treatment period.
Table 2. Hemodynamic Variables During Ischemia-Reperfusion in Single-Dose Studies
Before
Ischemia
5-Min
Ischemia
29-Min
Ischemia
60-Min
Reperfusion
120-Min
Reperfusion
24-h group
HR (beats/min)
Saline 230.0 6 3.7 231.7 6 4.0 241.7 6 6.5 238.3 6 7.0 231.7 6 6.5
CCPA 232.9 6 7.8 235.7 6 8.1 252.9 6 7.1 234.3 6 9.0 238.6 6 7.1
SBP (mm Hg)
Saline 93.8 6 3.6 88.5 6 3.8 87.7 6 7.9 76.7 6 2.5 70.0 6 1.0
CCPA 92.3 6 3.9 81.6 6 5.0 86.6 6 5.3 75.1 6 2.6 72.3 6 2.7
RPP (mm Hg/min 3 103)
Saline 21.6 6 1.0 20.5 6 1.1 21.4 6 2.4 18.3 6 0.8 16.2 6 0.4
CCPA 21.6 6 1.3 19.3 6 1.5 21.0 6 1.6 17.7 6 1.2 17.3 6 1.0
48-h group
HR (beats/min)
Saline 215.0 6 9.9 221.7 6 9.1 235 6 12.0 223.3 6 11.7 218.3 6 11.1
CCPA 224.3 6 6.5 228.6 6 9.4 232.9 6 6.1 221.4 6 8.3 221.4 6 6.7
SBP (mm Hg)
Saline 84.3 6 4.8 74.3 6 4.4 75.2 6 3.1 74.7 6 4.3 74.3 6 4.5
CCPA 83.3 6 1.9 71.4 6 2.2 74.1 6 1.8 74.0 6 2.3 73.4 6 2.7
RPP (mm Hg/min 3 103)
Saline 18.3 6 1.7 16.6 6 1.4 17.8 6 1.4 16.8 6 1.5 16.3 6 1.3
CCPA 18.6 6 0.5 16.3 6 0.9 17.2 6 0.4 16.4 6 0.8 16.3 6 0.7
Data presented are mean value 6 SEM. CCPA 5 2-chloro-N6-cyclopentyladenosine; HR 5 heart rate; RPP 5
rate–pressure product; SBP 5 systolic blood pressure.
Table 3. Hemodynamic Variables During Ischemia-Reperfusion in Long-Term Intermittent
Dosing Study
Before
Ischemia
5-Min
Ischemia
29-Min
Ischemia
60-Min
Reperfusion
120-Min
Reperfusion
HR (beats/min)
Saline 230.0 6 6.2 236.0 6 5.4 251.0 6 8.6 224.0 6 7.2 225.0 6 8.3
CCPA 227.3 6 5.2 230.9 6 5.8 233.6 6 5.8 220.9 6 7.9 223.6 6 8.1
SBP (mm Hg)
Saline 95.0 6 2.5 88.0 6 3.1 82.9 6 1.9 75.5 6 2.2 73.4 6 2.7
CCPA 90.6 6 3.3 81.5 6 3.3 78.8 6 2.8 75.5 6 2.5 73.5 6 2.5
RPP (mm Hg/min 3 103)
Saline 21.9 6 1.0 20.8 6 1.0 20.8 6 0.9 16.9 6 0.8 16.5 6 0.7
CCPA 20.5 6 0.8 18.9 6 1.0 18.5 6 0.9 16.8 6 0.7 16.3 6 0.6
Data presented are mean value 6 SEM. Abbreviations as in Table 2.
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Previous studies have reported desensitization of adenosine
A1 receptors after long-term exposure to agonists. These
include studies examining regulation of adenosine receptors in
the brain (20,21), kidney (22) and adipocytes (23–27) of the
rat, embryonic myocytes of the chick (28,29) and smooth
muscle DDT1 MF-2 cells of the hamster (30,31). Desensitiza-
tion occurred in a time- and dose-dependent and reversible
fashion; thus, long-term exposure to adenosine A1 receptor
agonists resulted in tolerance after 2 to 7 days in rat adipocytes,
24 to 44 h in chick embryo myocytes and 18 to 44 h in hamster
DDT1 MF-2 cells. Few studies have explored adenosine A1
receptor regulation in the mammalian myocardium. Lee et al.
(32) reported desensitization of rat atrial adenosine A1 recep-
tors after a 7-day intravenous infusion of N6-(phenyl-2R-
isopropyl)adenosine, a selective A1 receptor agonist. In the
study by Tsuchida et al. (17), the time course of the desensi-
tization was not investigated, but tolerance to the cardiopro-
tective effects of CCPA developed in the rabbit myocardium
between 6 to 72 h of a continuous infusion. Furthermore, in
that study, the 72-h CCPA group received a total in excess of
3 mg/kg of CCPA over a 3-day period, a 30-fold higher dose
than that shown to precondition the rabbit myocardium (14),
providing further evidence for a dose-dependent influence on
tachyphylaxis. All the cited studies, however, were either
undertaken in cell culture models continuously exposed to
adenosine analogues or performed in vivo using a continuous
intravenous infusion for administering the agonists. The time
and dose dependence of A1 receptor desensitization would
imply that reducing the dose frequency of administering the
agonist might delay the development of tolerance to its effects.
Interestingly, in a recent study by Casati et al. (33), the time
course of desensitization to the hemodynamic effects of CCPA
was investigated after twice-daily intraperitoneal administra-
tion of the agonist to spontaneously hypertensive rats. Toler-
ance to the bradycardic effect of CCPA, the main A1 receptor-
mediated action, did not develop for 21 days. These results
further support the finding of this study that the reduced
frequency of exposure to adenosine agonists delays or may
even prevent tachyphylaxis.
Time course of delayed preconditioning. The temporal
profile of the delayed phase of myocardial protection after
ischemic or pharmacologic preconditioning has recently been
described for various end points of ischemia-reperfusion in-
jury. The SWOP against myocardial necrosis in the rabbit
extends between 24 and 72 h after IPC (8), a time course
identical to that observed after pharmacologic preconditioning
with CCPA in the same species (19). Meng et al. (34) have
recently reported a delayed cardioprotection against postisch-
emic myocardial dysfunction in the rat 4 to 72 h after transient
alpha1-adrenoceptor activation with norepinephrine. Further-
Table 4. Infarct Size Data for Long-Term Intermittent Dosing Study
Group
No. of
Animals
Body
Weight
(kg)
Risk
Volume
(cm3)
Infarct
Volume
(cm3)
Saline 10 2.71 6 0.31 1.19 6 0.10 0.58 6 0.10
CCPA 10 2.85 6 0.11 1.12 6 0.08 0.31 6 0.05*
*p , 0.05 compared with corresponding saline-treated group (unpaired
Student t test). Data presented are mean value 6 SEM. CCPA 5 2-chloro-N6-
cyclopentyladenosine.
Figure 3. Percent infarction of the risk zone in long-term intermittent
dosing study. Ten days of intermittent treatment with CCPA resulted
in marked protection against infarction compared with vehicle pre-
treatment. Open circles indicate individual experiments; solid circles
represent the mean value 6 SEM for each group. **p , 0.01 versus
vehicle-treated group (unpaired Student t test).
Figure 4. Early hemodynamic effects of a 100-mg/kg bolus of CCPA at
the end of reperfusion in rabbits pretreated for 10 days with intermit-
tent CCPA (solid circles) or saline vehicle (open circles). A, Changes
in HR. B, Changes in SBP. Data shown are percent changes (6SEM)
from baseline values.
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more, a delayed protection against ischemia-reperfusion–
induced ventricular arrhythmias that extends between 24 to
72 h after brief periods of cardiac pacing has been described in
the canine myocardium (9). Late preconditioning against
myocardial stunning, recently described by Tang et al. (10),
seems to have a similar time course and is protective 12 to 72 h
after brief periods of myocardial ischemia in the conscious pig.
The prolonged nature of these protective effects, as opposed to
the short-lived “classic” preconditioning, which only lasts for 1
to 2 h after the preconditioning stimulus, potentially allows
“re-preconditioning” at 48 to 72-hour intervals, a time sched-
ule that maintains the myocardium in a protected state,
without development of tolerance, as shown in the present
study. We did not examine the protective effects of intermittent
CCPA administration beyond 10 days, but as with the brady-
cardic effect reported by Casati et al. (33), it is likely to be
extended to at least 21 days. Furthermore, because the dosing
schedule in our study was even less frequent than that used by
Casati et al. (33), it is possible that desensitization of adenosine
A1 receptors may be even further delayed or may not occur at
all.
Clinical relevance. Patients with unstable angina form a
reasonably well defined high risk group that might benefit from
pretreatment with agents that trigger or augment myocardial
preconditioning over a period of several days or weeks and
could maintain the myocardium in a protected state. Despite
conventional pharmacologic and interventional approaches,
approximately 9% of patients with unstable angina die or suffer
from myocardial infarction within 30 days (35). Although a
number of these patients may be “naturally” preconditioned by
their preceding ischemic episodes and therefore not gain
additional benefit from pharmacologic preconditioning, recent
evidence suggests that unless the episodes of preinfarct angina
occur during a narrow time window in relation to the infarct,
this protection is not observed (36,37). So far there has been no
direct evidence for the presence of a delayed phase of protec-
tion in the human myocardium. However, if such protection
does exist, and if its duration can be extended by intermittent
pharmacologic preconditioning, the myocardium could be
maintained in a protected state, with resultant enhanced tissue
tolerance and a slower rate of necrosis in the event the patient
has an acute myocardial infarction. Although the ultimate
treatment for myocardial infarction is prompt revasculariza-
tion, such cardioprotective strategies would enhance the time
window during which revascularization therapies can be ad-
ministered, and may improve the outcome in a select group of
patients with unstable angina.
Conclusions. We have shown that intermittent activation
of adenosine A1 receptors over a 10-day period, with a highly
selective agonist, maintains the rabbit myocardium in a pro-
tected or “preconditioned” state against ischemia-reperfusion
injury. In contrast to studies exploring maintenance of classic
preconditioning, we did not find any evidence of tolerance to
the cardioprotective or hemodynamic effects of CCPA over
this period. In view of the potential therapeutic application of
such a potent and prolonged protection, further studies are
warranted to explore the underlying mechanisms.
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